FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trialVolker Heinemann, Sebastian Stintzing, Michael Scholz et al.|The Lancet Oncology|2014Cited by 1.7k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trialSebastian Stintzing, Volker Heinemann, Dominik Paul Modest et al.|The Lancet Oncology|2016Cited by 417
Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) studySebastian Stintzing, Volker Heinemann, Lisa Miller‐Phillips et al.|European Journal of Cancer|2017Cited by 139
Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With <i>KRAS</i> Wild-Type Tumors in Metastatic Colorectal CancerDominik Paul Modest, Volker Heinemann, Sebastian Stintzing et al.|Journal of Clinical Oncology|2015Cited by 123
Cetuximab Plus Capecitabine and Irinotecan Compared With Cetuximab Plus Capecitabine and Oxaliplatin As First-Line Treatment for Patients With Metastatic Colorectal Cancer: AIO KRK-0104—A Randomized Trial of the German AIO CRC Study GroupNicolas Moosmann, Volker Heinemann, Ludwig Fischer von Weikersthal et al.|Journal of Clinical Oncology|2011Cited by 117